infusion (DLI) products are manufactured and administered to treat relapse after allogeneic hematopoietic stem cell transplantation. Reported clinical responses to DLIs vary broadly, even within the same group of patients. While there is an implicit recognition of the fact that different manufacturing protocols may have specific effects on different cell types, cryopreservation protocols are frequently derived from our experience in the cryopreservation of stem cell products and do not account for the heterogeneous functional nature of DLI T-cell populations. Here, we report the results of a prospective, multicenter trial on the effect of four different cryopreservation solutions that were used to freeze DLIs compared to control DLIs that were refrigerated overnight.
STUDY DESIGN AND METHODS:
Cryopreserved postthawed and refrigerated specimens were analyzed side by side for their T-cell subpopulation content and viability, as well as T-cell proliferation, cytokine secretion, and cytotoxic activities.
RESULTS: This study indicates that "homemade" 10% dimethyl sulfoxide (DMSO) results in reduced viability of different CD41 T-cell populations, including T-helper, Tcytotoxic, and T-regulatory populations, and a decrease in their proliferative and cytotoxic response to immunologically relevant stimuli, while the use of solutions containing 5% DMSO with intracellular-like cryoprotectant stabilizers maintains T-cell function at levels similar to refrigerated control samples.
CONCLUSION:
This study has important implications in determining the best cryoprotectant solution for specific clinical applications in allogeneic immunotherapy.
P atients with hematologic malignancies who relapse after allogeneic hematopoietic stem cell (HSC) transplantation have a dismal prognosis.
Reestablishing disease control through donor lymphocyte infusion (DLI) is one accepted approach, as this can invoke graft-versus-tumor effects mediated by recognition of minor histocompatibility antigens and tumor antigens on malignant cells. 1 DLI has been successful in relapsed chronic myeloid leukemia with greater than 70% sustained response rates 2, 3 and is being used with different degrees of efficacy in other hematologic diseases. [3] [4] [5] [6] [7] [8] Some of these DLI products can also be modified and extensively manipulated to address specific therapy challenges for patients undergoing allogeneic HSC transplantation. For example, in some cases, T cells are used for their cytotoxic activity in the context of chimeric antigen receptor T-cell therapies against cancer [9] [10] [11] [12] [13] or after stimulation with antigen-presenting cells to be directed against virally infected cells (e.g., cytomegalovirus, adenovirus, or Epstein-Barr viruses).
14 Minimally manipulated DLIs are often collected and processed around the time of HSC donation and then cryopreserved and stored in the vapor or liquid phase of liquid nitrogen until they are needed. When lymphocytes are cryopreserved in solutions containing dimethyl sulfoxide (DMSO) using a controlled-rate freezer and are stored in liquid nitrogen, they can remain viable for long periods. 15 For many years, DMSO at a final concentration of 10% has been the standard cryoprotectant for freezing HSCs. Unfortunately, the transfusion of DMSO contained in thawed cellular therapy products may cause nausea, vomiting, headache, flushing, chest tightness, hypotension, hypertension, bradycardia, or abdominal cramps. [16] [17] [18] [19] To reduce these potential toxicities, several groups have investigated the viability of cells, primarily peripheral blood stem cells (PBSCs) that have been cryopreserved with lower concentrations of DMSO, and some have found that the postthaw recovery of PBSCs stored in 5% DMSO is superior to PBSCs stored in 10% DMSO. [20] [21] [22] Unfortunately, compared with PBSCs, there is a lack of understanding about how T-cell populations tolerate the freeze and thaw process. Several studies performed on a variety of cryopreserved related donor leukocyte products found that CD31 postthaw cell recoveries ranged from 50% to 90%. 15, 23, 24 However, the heterogeneous nature and/or processing of the clinical products did not allow a fair comparison between different methods of cryopreservation. The goals of this study were to identify whether cryopreservation damages specific T-cell subpopulations in clinical-grade DLI products and to determine the effect that different methods of cryopreservation which use different DMSO concentrations have on maintaining viability, cytotoxicity, proliferation, and cytokine production of T-cell populations. To address these goals we performed an interlaboratory, prospective trial where a leukapheresis product was collected from three unmobilized peripheral blood donors at each of four sites for a total of 12 leukapheresis collections. The cells were frozen at each site using the same cryopreservation methods and the cryopreserved specimens were transported to a reference laboratory for analysis. We assessed postthaw recoveries and viabilities of total nucleated cells and specific Tcell subpopulations. We also analyzed the functional activity of postthawed CD31 cells by evaluating their proliferation response and immunomodulatory and cytotoxicity activities.
MATERIALS AND METHODS

Study design
This is a prospective, multicenter study to collect and cryopreserve DLI products using clinically accepted protocols. Healthy donors were recruited following institutional policies under institutional review board-approved protocols and informed consent was obtained. Three subjects were enrolled in each of four different institutions in the United States (Hoxworth Blood Center, University of Cincinnati, Cincinnati, OH; University of Utah, Salt Lake City, UT; Dartmouth Medical School, Lebanon, NH; and University of Minnesota, Minneapolis, MN). All apheresis procedures were performed following institutional protocols for a whole blood processing of 10 L using Food and Drug Administration-licensed apheresis machines (COBE Spectra, TerumoBCT). The peripheral blood mononuclear cells (PBMNCs) collected from three donors at each site were each divided into five aliquots. Four aliquots were frozen using four different cryopreservation methods and the fifth aliquot was maintained at 1 to 68C as a fresh control.
PBMNC processing
Although each site had its own standard operating procedures for cell manipulation and processing, a common set of cryopreservation protocols was used by the four institutions to standardize the procedures. Cell cryopreservation was performed to obtain 25-mL products containing 1 3 10 7 cells/mL. Four cryopreservation solutions were compared. The first two, "homemade" 5% DMSO and 10% DMSO, were prepared at each site using a 1:1 mixture of cells resuspended in freezing buffers as shown in Table 1 . The other two were commercial intracellular-like cryopreservation solutions. CryoStor CS5 and CryoStor CS10 (BioLife Solutions) are intracellular-like in ionic-osmotic formulation, in contrast to traditional isotonic-based cryopreservation vehicles. 25 They are composed of large and . When using the homemade 5 and 10% DMSO cryopreservation solutions, cell products were first diluted in a suspension buffer, and then a cryopreservation buffer was added for a total volume of 25 mL. When using the commercial cryopreservation solutions, 24 mL of prechilled CryoStor CS5 or CryoStor CS10 was added to 1 mL of cells resuspended in a mixture of Plasma-Lyte A (PlasmaLyte, Baxter Healthcare Corp.) containing 140 mEq/L sodium, 5 mEq/L potassium, 3 mEq/L magnesium, 98 mEq/L chloride, 27 mEq/L acetate, and 23 mEq/L gluconate (294 mOsm/L; pH 7.4), and 2% human serum albumin (HSA). Cells in their freezing solutions were mixed and placed in 25-mL cryobags (CS25, Origen Biomedical). All products were cryopreserved using a controlled-rate freezer according to each site's standard operating procedure that accounted for heat of fusion release and a freezing rate of 18C/min until a temperature of 2208C was reached and then 108C/min until a temperature of 2758C was achieved. Immediately after the freezing process was finished, the frozen cells, together with their fresh (unfrozen) control, were shipped overnight to a central laboratory. Fresh control cells were shipped in an insulated shipping container at 1 to 98C, at a concentration of 1 3 10 7 cells/mL in PlasmaLyte with 2.5% HSA. Frozen specimens were shipped in LN 2 vapor phase in temperature-controlled dry shippers. Upon arrival at the central laboratory, fresh and frozen specimens were thawed for immediate testing as indicated below.
Immunophenotypic and viability analysis
Frozen cell products were thawed in a 378C water bath until no ice was observed inside the bags. Thawed products were washed twice to remove DMSO with 103 the volume of Advanced RPMI-1640 (Gibco) supplemented with 10% fetal calf serum (FCS), 5.9% dextran, and 10 mmol/L HEPES, pH 7.4. Cell counts were performed and cells were stained for analysis by flow cytometry. Lymphocyte subset populations were identified by staining with CD3-APC-Cy7, CD4-PECy7, CD8-FITC, CD19-PE, CD56-APC, and 7-aminoactinomycin D (7-AAD) was used to identify viable lymphocyte subsets. T-cell subpopulation discrimination and viability was evaluated with CD3-APCCy7, CD4-PECy7, CD8-PE, CD45RO-APC, CD45RA-FITC, and 7-AAD, and T-regulatory cells (T-regs) with CD3-APCCy7, CD4-PECy7, CD25-PE, CD45RO-APC, CD45RA-PerCP-Cy5.5, and 7-AAD. Cells were permeabilized after staining with CD3-APC-Cy7, CD4-PECy7, CD25-PE, CD45RO-APC, CD45RA-PerCP-Cy5. bright /CD45RO1/CD45RA-. Viability was analyzed by determining the percentage of 7-AAD1 cells present in each of these populations. T-reg viability could not be directly measured in FoxP3-stained specimens, because these were fixed and permeabilized. All antibodies used for staining were obtained from BD Biosciences.
Stimulation of T cells followed by analysis of secreted cytokines and proliferation and cell cycle
T cells from each donor (fresh and thawed) were stimulated and grown in culture. First PBMNCs were placed in 150 3 25-mm coated tissue culture plates (Sigma) and incubated at 378C, 5% CO 2 for 3 hours to deplete monocytes. The nonadherent cells were collected and filtered through a 100-mm filter (Fisher) to remove debris. The recovered cells were counted using an automated cell counter (Coulter) and were then resuspended at 10 6 cell/mL and plated in 24-well round bottom plates containing 1 mL of media consisting of Advanced RPMI 1640 (Gibco), 10% FCS, 2 mmol/L L-glutamine (Gibco), 100 U/mL IL-2 and 10 mg/ mL phytohemagglutinin (PHA, Sigma). After 48 hours, cells were harvested and spun down. The supernatant was collected for chemokine and cytokine analysis and the cell pellet was retained to measure the cell cycle status of the cells. The chemokine and cytokine profile of the supernatant was analyzed using multianalytic profiling beads (MILLIPLEX MAP Human Cytokine/Chemokine Magnetic Bead Panel I Immunology Multiplex Assay kit, EMD Millipore) according to the manufacturer's instructions. The cell cycle status of the stimulated cells was determined by staining cells with 2 0 -bromodeoxyuridine (BrdU, 20 mmol/L). BrdU was added directly to the culture medium containing PHA-stimulated lymphocytes and then incubated at 378C in 5% CO 2 for 40 minutes. The treated cells were counted in a hemocytometer and then stained with anti-CD3-APC-Cy7, fixed, and permeabilized, to expose the incorporated BrdU, and stained again with specific fluorescent anti-BrdU-FITC antibodies and 7-AAD according to the manufacturer's directions (BD Biosciences). Supernatant was collected from the culturing process and was stored frozen until cytokine testing was executed. All flow acquisition and analysis was performed using a flow cytometer (FACSCanto with Diva software, BD Biosciences).
Chromium-51 ( 51 Cr) release stress cytotoxicity assay
To assess cytotoxicity of cryopreserved T cells, a 6-hour 51
Cr-release assay was performed under stress conditions. A total of 10 leukapheresis products that had been frozen with each of the four methods of cryopreservation were analyzed for their ability to induce spontaneous cytotoxicity of allogeneic PHA-stimulated blast cells. To induce an additional stress, all the specimens were frozen in parallel a second time using the same cryopreservation solution (homemade 5% DMSO solution) and thawed using the same buffer and conditions as indicated above. A fresh positive control of MNCs from a different donor was run for each assay. Cells were then processed as follows. A total of 10 6 cells were incubated in four replicates for 6 hours with 51
Cr-labeled PHA-stimulated blasts following standard methods. 26 The target:effector ratios used were 50:1, 25:1, 12.5:1, and 6.25:1. After incubation, the lymphocyte-target cell mixture was spun and the supernatant was analyzed for the presence of 51 Cr, an indication that the target cell was lysed by cytotoxic T lymphocytes. A daily fresh sample of peripheral blood white blood cells (WBCs) from different donors was run in parallel as a technical control. The percentage of specific lysis for each sample was calculated as experimental release2spontaneous release maximum release2spontaneous release 35% cytotoxicity:
A quality control (QC) sample for each target was also tested. Here, a portion of labeled target cells was incubated in medium alone (spontaneous lysis wells) and a portion was incubated with 0.2% Triton X-100 detergent solution (maximum lysis wells). QC values were calculated as Cytotoxicity % ð Þ5 spontaneous release=maximum release ½ 3100
and presented as the mean of triplicate samples. Lytic units were calculated as previously described. 26 
Statistical analysis
Results are presented as mean 6 standard deviation (SD) except for normalized cytokine release data, which is given as mean 6 standard error of the mean (SEM). Differences were analyzed using one-way or two-way analysis of variance (ANOVA) with Dunnett's multiple comparisons (Graphpad Prism software v. 6.07). Significance was defined as p values of less than 0.05.
RESULTS
Cellularity of postthaw DLI products
We performed a total nucleated cell count for each sample that was maintained overnight in cold storage and for cryopreserved DLI specimens upon thawing. A 5-mL aliquot of each specimen was analyzed. As depicted in Fig.  1A , there was a loss in cellularity (mean, approx. 22%; p < 0.01) in frozen-thawed samples compared to overnight cold-stored control samples. There were no significant differences in cell counts among samples frozen with different cryopreservation methods (Fig. 1A) .
Immunophenotyping of lymphocyte populations
Cryopreservation resulted in an enrichment of T cells (approx. 1.5-to 1.7-fold), especially CD41 T lymphocytes (approx. 1.5-to 2-fold enrichment) among all live cells compared with the control (Fig. 1B) . Interestingly, homemade 10% DMSO cryopreservation resulted in a significant enrichment of na€ ıve, but not CD45RA-memory, CD41 T cells compared with fresh control cells (Fig. 1C ) and resulted in a modest enrichment of the B-cell content compared with CryoStor CS5 (p < 0.05, Fig. 1B ). Immunophenotypic analyses of overnight cold-stored (i.e., control cells) and cryopreserved cells showed no significant difference in the content of CD81 T-cell or NK-cell populations (Fig. 1B ) or in T-reg populations (Fig. 1D ). These data indicate that all the cryopreservation media tested, except 10% DMSO, resulted in relative enrichment of CD41 lymphocyte populations.
Viability of CD41 T cells in homemade 10% DMSO is significantly decreased
Although all cryopreservation methods trended toward a decrease in the viability of the different T-cell populations analyzed, these differences did not reach significance when a stringent two-way ANOVA statistical analysis was used, except for the group of specimens cryopreserved in homemade 10% DMSO, which had an approximately 5% lower viability in the overall population of CD31 T cells. Specifically, for CD41, but not for CD81, T cells in the homemade 10% DMSO had an approximately 8% decreased viability (p < 0.05; Figs. 2A and 2B) . Analysis of the viability of T-reg cells indicated that T-reg numbers, either mature or na€ ıve, cryopreserved in homemade 10% DMSO were approximately 12% lower compared with the fresh control (p < 0.05; Fig. 2C ). Interestingly, na€ ıve, but not mature, T-reg cells cryopreserved with CryoStor CS10 also had a 6% decrease in their viability relative to the control (p < 0.05, Fig. 2C ). These data suggest that the viability of T-helper and T-reg populations are specifically reduced when a homemade 10% DMSO cryopreservation solution is used. Interestingly, these differences were mirrored but significantly ameliorated for those specimens cryopreserved in CryoStor CS10, while the highest viability was present for those lymphocytes cryopreserved with CryoStor CS5. These data indicate that cryopreservation of CD41 (helper or regulatory) T cells in homemade 5% DMSO or CryoStor CS5 may be preferable over solutions containing 10% DMSO to maintain their viability after thawing.
Cell cycle analysis of in vitro stimulated T cells
Using a combination of surface CD3 antigen labeling, 7-AAD, and anti-BrdU staining on BrdU pulsed cells, we analyzed the level of proliferation and cell cycle status of T cells from overnight cold-stored and cryopreserved specimens. All groups show a similar response to the stimulants PHA and IL-2 except those T cells cryopreserved in homemade 10% DMSO, which showed a significantly decreased (approx. 45%) proliferation response as assessed by a poor incorporation of BrdU and a significant arrest in the G2/M phase of the cell cycle (Fig. 2D) . These data support a decreased proliferative capacity of DLI products cryopreserved with 10% DMSO.
Cytokine release assays of in vitro stimulated lymphocytes
A multiplex bead assay was used for quantification of multiple cytokines in the supernatant of 48-hour cultured DLI products in the presence of IL-2 and PHA. While the secretion of cytokines IL-6, IL-7, IL-5, and IL-8 was not affected by the cryopreservation or the method of cryopreservation (Figs. 3A-3D ), the secretion of lymphocyte-derived proinflammatory cytokines IFN-c or IL-13 was significantly diminished in thawed DLI products conventionally cryopreserved in 10% DMSO (Figs. 3E and 3F) . Interestingly, IL-12 p70 and IL-1b production were impaired in conventionally frozen DLI in either homemade 5 or homemade 10% DMSO (Figs. 3G and 3H ). This observation is DMSO-cryopreserved DLI products, while being maintained in CryoStor-frozen products at levels similar to fresh products. Since these specimens had been monocyte depleted, these results further suggest a specific T-cell defect in the secretion of these inflammatory cytokines in those products frozen with homemade 10% DMSO. These data further suggest that the CryoStor solutions may better preserve monocyte cytokine-secretion functions. Finally, all cryoprotectants except CryoStor CS5 resulted in diminished production of the T-reg-dependent anti-inflammatory cytokine IL-10, and homemade 10% DMSO cryopreservation resulted in a significantly reduced secretion of IL-10 when compared with CryoStor CS5 (Fig. 3K) . Together, these data suggest that CryoStor CS5 maintains in vitro cytokine secretion derived from T-helper, T-reg, and monocytes better than the other cryopreservation solutions and especially homemade 10% DMSO.
Lymphocytes cryopreserved in homemade 10% DMSO are deprived of cytotoxic activity upon repeated freezing-thawing stress
To determine whether the process of cryopreservation further decreased the NK cytotoxic activity of these populations, we devised a stress test to analyze cytotoxicity with a 51
Cr release assay. Specimens were thawed and refrozen with a common schema for all compared groups using the homemade 5% DMSO cryopreservation solution. In these stress conditions, all four cryoprotection media resulted in similar cell viabilities for thawed products (Fig. 4A) . However, although three of four methods of cryopreservation were able to maintain a T-cell-mediated cytotoxic response (Fig.  4B) , the homemade 10% DMSO cryopreservation solution failed to maintain any cytotoxic activity (p < 0.001; Fig. 4B ), further confirming the existence of a profound functional impairment. Both CryoStor solutions maintained levels of cytotoxic alloreactivity close to the positive controls.
DISCUSSION
The process of cryopreservation of DLI products, like other cell cryopreservation procedures, involves a combination of perturbations and biologic stresses that can damage cells during each of the steps of cryopreservation including prefreeze cooling, controlled-rate freezing, cryostate maintenance, thawing, and rewarming. These stresses include osmotic-ionic imbalances, metabolic imbalances, free radical accumulation, dehydration, membrane damage, and extra-and intracellular ice formation, each of which can lead to decreased postpreservation outcomes. 27 This study was designed to identify prospectively whether specific methods of cryopreservation on unprimed leukapheresis products resulted in any harmful effects on the viability and/or function of specific lymphocyte populations, in particular, in the context of lymphocyte products that are destined for allogeneic transplantation. The study used clinical-scale leukapheresis products processed independently by four experienced cell therapy centers. Each site shipped their frozen specimens overnight to a central site where all cryopreserved specimens and fresh controls were processed at the same time in parallel.
Our results indicate that all the cryopreservation methods resulted in a similar loss of cells during the cryopreservation process. We did not reliably quantify the content of MNCs among all nucleated cells in the postthaw products, but it is very likely that the majority of the average 22% cells lost during the cryopreservation process were residual granulocytes as previously described.
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CD41 T cells are well known for their helper roles including those that promote antibody class switching, enhancing the development of the cytotoxic T-lymphocyte activity of CD81 T cells and their ability to be functional CD45RA-memory cells. Also, CD41 T cells can acquire cytotoxic activity and directly kill infected, transformed, or allogeneic MHC Class II1 (class II) cells. CD41 T cells with cytotoxic activity have been identified within the Th0-, 29, 30 Th2-, 31 and T-reg-32 effector T-cell subsets, but most often are described as being Th1-like and characterized by the production of IFN-c or as polyfunctional with production of some combination of the cytokines IFN-c, TNF-a, and IL-2. 33 The cytotoxic activity of CD41 T cells is further enhanced in the presence of IL-2. approximately 12% decreased compared with the fresh control. This effect seems to be linked to the use of 10% rather than 5% DMSO in the cryopreservation solution since the viability of T-reg populations frozen in CryoStor CS10 was also, albeit at lower T-reg recoveries (i.e., decreased by approx. 6%). The complete set of data strongly suggests that the cryopreservation of CD41 (helper or regulatory) T cells in homemade 5% DMSO or CryoStor CS5 may be preferable over solutions containing 10% DMSO to maintain their viability after thawing. Furthermore, homemade 10% DMSO-cryopreserved DLI products had an approximately 50% reduced proliferative response, an approximately 30% to 70% reduced secretory response of the proinflammatory cytokines IFNc, or IL-13 and an abrogated cytotoxicity activity. This effect was seen especially, when submitted to a second cycle of freeze-thaw, indicating the existence of a sublethal lesion of T cells that results in reduced sensitivity to mitogen stimulation and alloreactive cytotoxic activity. This effect seems to particularly affect CD41 T-helper, cytotoxic, and regulatory cells (and possibly NK cells). The loss of viability and function of CD41 cells is especially noteworthy since IFN-c-expressing CD41 cells have been shown to be responsible for immunologic rejection of different tumors in animal models. [34] [35] [36] The frequency or viability of B-lymphocytes seems not to be affected by the cryopreservation method, and monocyte-derived cytokine secretion (IL-10) seemed to be protected similarly by both CryoStor solutions (5 or 10%) while being significantly diminished when using homemade 5 or 10% DMSO solutions. This influence on monocyte function seems to reproduce the effect seen in the predominantly myeloid committed population of CD341 PBSCs. 25 The US Foundation for the Accreditation of Cellular Therapies (FACT) 37 requires that a procedure is validated or verified as appropriate and to have a stability program that evaluates the viability and potency of cryopreserved cellular therapy products. Due to the difficulties in standardizing assays to define the potency of DLI products in relation to clinical applications, most transplantation and cellular therapy programs address the aforementioned mandate by analyzing the viability of the overall population CD31 cells, but not of T-cell subpopulations, and do not use any functional assay to determine the potency of their T-cell products. Therefore, significant variations exist between different transplant centers in the methods used for cryopreservation of cells for transplantation. Based on its historical use in the cryopreservation of other hematopoietic cells, the most frequently used cryopreservative for T cells is 10% DMSO within some isotonic (extracellularlike) diluent. 38 However, other cryopreservation solutions have been shown to provide better viabilities in specific cell types. [20] [21] [22] 25 In the cryopreservation of lymphocyte populations, a comparison of the postthaw cellular recoveries of CD341, T-, and NK-cell subsets from mobilized PBSCs stored in 2, 4, 5, and 10% DMSO found the best postthaw recovery in cells stored in 4 or 5% DMSO. 39, 40 While the postthaw recoveries of HSCs and
WBCs have been similar in 5 and 10% DMSO, almost all of the studies assessed cells from granulocyte-colonystimulating factor-mobilized PBSC components and there has been no functional studies performed on the effect of the type of cryoprotectant method on lymphocyte cytotoxicity.
In the clinical context of DLI applications, the loss of cytotoxicity induced by cryopreservation with 10% DMSO is likely to result in loss of potency which could partly explain the huge variability in the results reported by different groups, [4] [5] [6] with initial clinical responses to DLI ranging from 15% to 29% in acute myeloblastic leukemia and from 5% to 27% in acute lymphoblastic leukemia. 3, 7, 8 Interestingly, homemade 10% DMSO is the preferred method to cryopreserve chimeric antigen receptor T cells 9 and antiviral T cells. 41 It is quite possible that the excellent clinical results of these products are partly due to the selective elimination of allogeneic reactivity in T-cell clones.
Our study was performed to mimic human clinical applications. Cryopreservation solutions are generally classified as ancillary materials (when washed postthaw) or excipients (when included in final administered product) within a cell therapy process. Often, what is utilized as the cryopreservation cocktail is a vehicle solution (i.e., isotonic saline or plasma) with a cryoprotectant (i.e., DMSO), each of which may have regulatory approval for separate uses, but is still considered an off-label use of each component for a nonapproved application (cryopreservation). The fact that the 5% DMSO cryopreservation also contains HES (Table 1 ) and the CryoStor solutions contain both permeant and nonpermeant solutes that stabilize the cell membrane raises the possibility that the nonpermeant osmolarity effect of this solution is protective on T-cell damage as previously published for HSCs. 39 In practice, homemade cryopreservation cocktails are rarely subjected to final testing for sterility, endotoxin, or efficacy as might be required for other reagents. As such, the use of preformulated complete cryopreservation solutions, manufactured to cGMP standards and subjected to testing standards, offers several advantages from a quality or regulatory perspective as a material within a cell therapy process. The use of a cGMP produced product provides a level of consistency in formulation and an efficacy that is likely missing from one that is homemade. In conclusion, the results from this study demonstrate that use of a homemade 10% DMSO cryopreservation solution can result in significant loss of potency of sensitive T-cell populations and that CryoStor CS5 or homemade 5% DMSO may result in significant maintenance of the potency of DLIs and potentially may result in a decreased variability in DLI product potencies.
